Genetically Engineered Biologic Drugs in Management of Children with Bronchial Asthma
Svetlana V. Zaytseva,
Anna U. Tomilova,
Olga V. Zaytseva,
Olga B. Voronina,
Olga A. Murtazaeva,
Valeriy A. Mukhortykh,
Irina N. Tsymbal https://doi.org/10.15690/pf.v18i6.2325
Abstract
Current article represents the modern clinical guidelines on management of severe bronchial asthma (BA) in children and practical use of genetically engineered biologic drugs.
Clinical efficacy and safety of omalizumab has its special role. Efficacy analysis was carried out in real-life' clinical setting (considering high economical expenses of biological treatment) to estimate effective response predictors and principles of patients selection for such therapy. Two years of anti-IgE treatment experience in inpatient pediatric department settings demonstrates that omalizumab inclusion to treatment of children with severe asthma resistant to standard therapy allows to solve asthma symptoms, to forgo high doses inhaled glucocorticosteroids, to improve lung function parameters, and to increase significantly quality of life in 95% of our patients.
Keywords
Supporting agencies: Clinical study was funded by Federal State Clinical Pediatric Centre of Federal Medico-biological Agency and Science, Moscow, Russian Federation.
About the Authors
Svetlana V. Zaytseva
Moscow State University of Medicine and Dentistry named by A.I. Yevdokimov, Ministry of Healthcare; Federal Scientific Center for Children and Adolescents FMBA of Russia
Russian Federation
Disclosure of interest:
Russian Federation
Svetlana V. Zaytseva, MD, PhD
eLibrary SPIN: 4477-6498
20 Moskvorechye Str., 115409, Moscow
Disclosure of interest:
Not declared
Anna U. Tomilova
Federal Scientific Center for Children and Adolescents FMBA of Russia
Russian Federation
Disclosure of interest:
Russian Federation
Anna U. Tomilova, MD, PhD
eLibrary SPIN: 8695-4392
20 Moskvorechye Str., 115409, Moscow
Disclosure of interest:
Not declared
Olga V. Zaytseva
Moscow State University of Medicine and Dentistry named by A.I. Yevdokimov, Ministry of Healthcare
Russian Federation
Disclosure of interest:
Russian Federation
Olga V. Zaytseva, MD, PhD, Professor
Scopus Author ID: 57189354989
20, b. 1 Delegatskaya Str., 127473, Moscow
Disclosure of interest:
Not declared
Olga B. Voronina
Federal Scientific Center for Children and Adolescents FMBA of Russia
Russian Federation
Disclosure of interest:
Russian Federation
Olga B. Voronina, MD
20 Moskvorechye Str., 115409, Moscow
Disclosure of interest:
Not declared
Olga A. Murtazaeva
Moscow State University of Medicine and Dentistry named by A.I. Yevdokimov, Ministry of Healthcare
Russian Federation
Disclosure of interest:
Russian Federation
Olga A. Murtazayva, MD, PhD
20 Moskvorechye Str., 115409, Moscow
Disclosure of interest:
Not declared
Valeriy A. Mukhortykh
Federal Scientific Center for Children and Adolescents FMBA of Russia
Russian Federation
Disclosure of interest:
Russian Federation
Valeriy A. Mukhortykh, MD, PhD
eLibrary SPIN: 3437-4081
20 Moskvorechye Str., 115409, Moscow
Disclosure of interest:
Not declared
Irina N. Tsymbal
Federal Scientific Center for Children and Adolescents FMBA of Russia
Russian Federation
Disclosure of interest:
Russian Federation
Irina N. Tsymbal, MD, PhD
20 Moskvorechye Str., 115409, Moscow
Disclosure of interest:
Not declared
References
1. Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals GuidelinesRecommendations for severe asthma. Allergy. 2021;76(1):14–44. doi: 10.1111/all.14425
2. GINA. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma, 2021. Available online: www.ginasthma.org. Accessed on November 3, 2021.
3. Instructions for medical use of the drug Xolair®. Registration number: ЛП-004376 dated May 21, 2021. (In Russ).
4. Zyryanov SK, Butranova OI. Genetically engineered drugs for treatment of bronchial asthma: recent achievements. Pulmonologia = Russian Pulmonology. 2018;28(5):584–601. (In Russ). doi: 10.18093/0869-0189-2018-28-5-584-601
5. Novik GA, Avdeev SN, Solovkina YV. Disease-modifying treatment of asthma: role of omalizumab. Pulmonologia = Russian Pulmonology. 2020;30(6): 822–830.(In Russ). doi: 10.18093/0869-0189-2020-30-6
6. Sheehan WJ, Krouse RZ, Calatroni A, et al. NIAID- sponsored InnerCity Asthma Consortium. Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma. J Allergy Clin Immunol Pract. 2020Oct;8(9):3021-3028.e2. doi: 10.1016/j.jaip.2020.03.051. Epub 2020 May 4. PMID: 32376491
7. Fu Z, Xu Y, Cai C. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a metaanalysis. J Asthma. 2021;58(10):1350–1358. doi: 10.1080/02770903.2020.1789875
8. Corren J, Kavati A, Ortiz B, et al. Efficacy and safety of omalisumab in children and adolescens with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc. 2017;38(4): 250–263. doi: 10.2500/aap.2017.38.4067
9. Kaplan A, FitzGerald JM, Buhl R, et al. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management. NPJ Prim Care Respir Med. 2020;30(1):50. doi: 10.1038/s41533-020-00205-9
10. Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485. doi: 10.1016/j.jaci.2015.09.008
11. Esquivel A, Busse WW, Calatroni A, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med. 2017;196(8):985–992. doi: 10.1164/rccm.201701-0120OC
12. Busse WW, Humbert M, Haselkorn T, et al. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2020;124(2):190–196. doi: 10.1016/j.anai.2019.11.016
13. Periodic Safety Update Report: Novartis. Data on File Novartis from December 31, 2019. (Периодический отчет по безопасности от 2019, Новартис)
14. Noop A, Johansson SGO, Adedoyin J, et al. After 6 years with Xolair; 3-year withdrawal follow-up. Allergy. 2010;65(1):56–60. doi: 10.1111/j.1398-9995.2009.02144.x
15. Baena-Cagnani CE, Teijeiro A, Canonica GW. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr Opin Allergy Clin Immunol. 2015;15(3):267–271. doi: 10.1097/ACI.0000000000000161
Review
For citations:
Zaytseva S.V., Tomilova A.U., Zaytseva O.V., Voronina O.B., Murtazaeva O.A., Mukhortykh V.A., Tsymbal I.N. Genetically Engineered Biologic Drugs in Management of Children with Bronchial Asthma. Pediatric pharmacology. 2021;18(6):460-468. (In Russ.) https://doi.org/10.15690/pf.v18i6.2325
Views:
1401
Email this article 